N.V. Korobov – Ph.D.(Med.), Associate Professor, Head of department, Scientific Center for Expert Evaluation of Medicinal Products
N.M. Kotov – Chief Specialist, Central Research Institute of the Health Organization and Informatics
G.S. Lebedev – Dr.Sc.(Eng.), Deputy Director, Central Research Institute of the Health Organization and Informatics
L.A. Loshakov – Dr.Sc.(Pharm.), Porofessor, Faculty Fundamental Medicine, Lomonosov Moscow State University
A.N. Yavorsky – Dr.Sc.(Med.), Professor, Scientific Secretary, Scientific Center for Expert Evaluation of Medicinal Products
T.A. Efremova – Expert, Scientific Center for Expert Evaluation of Medicinal Products
V.V. Kholokhon – Post-graduate Student, Faculty of Fundamental Medicine, Lomonosov Moscow State University
According to the World Health Organization, 130–150 millions of people suffer from chronic hepatitis C all over the world, and about 350–500 thousands of people annually die due to hepatitis and related diseases. Antiviral therapy is effective for this disease, but the availability of diagnosis and treatment remains low due to economic reasons. Hepatitis C has been recognized by the Government of the Russian Federation as socially significant disease.
Development and application of the most effective drugs in current clinical practice (inhibitors of proteases and inhibitors of viral polymerases), having a direct antiviral effect to the pathogen, allowed to achieve of convalescence and increased life expectancy of millions of patients suffering from hepatitis C. Scientific developments in the virology, genetics and molecular biology (identification of 6 genotypes and 27 subtypes of hepatitis C: that affect treatment approaches, clinical trials and pharmacotherapy of the disease in developed countries), contributed to achievement of favorable outcomes.
The accumulated results of studies of practical application of antiviral drugs have caused a radical update of clinical guidelines and recommendations for the prevention, diagnosis and treatment of chronic hepatitis C.
Application of information technologies will significantly improve the efficiency of selection of the most suitable drugs for the treatment of patients in each case, and will ensure the conclusiveness and value of assignments. Purpose of information support will be to create an effective information model of health technology assessment and formalized database, and each doctor will be able to have free access to it.
The introduction of such an information system into clinical practice will improve the efficiency of treatment by:
• automated selection of the most suitable treatment regimen for the individual patient based on information about his condition and stage of the disease;
• comparative analysis of clinical outcomes for selected treatments;
• choice of optimal pharmacotherapy by doctor;
• informed consent from the patient about his participation in deciding about the choice of treatment regimens;
• reduction of working time for doctor in conditions of limited resource;
• updating database with information about the effectiveness and safety of treatments from medical historys with similar disease characteristics and using the results for selection of personalized treatment for new patients.
Hepatitis C. URL: http//www.who.int/mediacentre/factsheets/fs164/en/.
D. The global burden of hepatitis C. // Liver Int. 2009. V.29. Suppl. 1. P. 74
M., Nayagam S., Thursz M. Viral hepatitis in resource-limited countries and
access to antiviral therapies: current and future challenges // Future Virol.
2013 Apr. V. 8(4). P. 371 – 380.
D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., Simmonds P.
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:
Updated criteria and genotype assignment Web resource // Hepatology. 2014. V.
59. P. 318 – 327.
Library Cataloguing-in-Publication Data. Guidelines for the screening, care and
treatment of persons with hepatitis C infection. April 2014.
Clinical Practice Guidelines: Management of hepatitis C virus infection //
Journal of Hepatology. 2014. V. 60. P.
392 – 420.
M.H., Agarwal K., Austin A. et. al. Review article: 2014 UK consensus
guidelines – hepatitis C management and direct-acting anti-viral therapy //
Aliment Pharmacol Ther. 2014. V. 39. P. 1363 – 1375.